Anti-PDL1 chimeric switch receptor modified T-cell therapy (Marino Biotechnology)

N/A

Report date: 2022/11/25 17:24:46

Base Information

Drug NameAnti-PDL1 chimeric switch receptor modified T-cell therapy (Marino Biotechnology)
Drug Alias Name抗PD-L1嵌合转换受体修饰的T细胞疗法Anti-PD-L1 CSR T cells (Marino Biotechnology)Autologous anti- PD-L1 CSR T cells (Marino Biotechnology)Anti-PDL1 chimeric antigen receptor T-cell therapy (Marino Biotechnology)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionT lymphocyte replacementsProgrammed death-ligand 1 blockers
TargetsProgrammed death-ligand 1
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaPending
Originator CompaniesBeijing Marino Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBeijing Marino Biotechnology Co Ltd
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A